Anti-GPC3 Constructs for Cell-Surface HCC Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma (HCC) are limited by the expression of ATP binding cassette transporters in liver cells, which export chemotherapeutic agents, and surgery is only effective in early stages, with late-stage treatments offering minimal survival benefit, highlighting the need for novel therapeutic methods targeting GPC3 overexpression.
Innovation Solution
Development of anti-GPC3 constructs, such as antibodies and chimeric antigen receptors, that specifically recognize cell surface-bound GPC3 with high affinity, enabling targeted T-cell killing of GPC3-expressing cancer cells and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat HCC, then cancer cells can be targeted, but the effectiveness is limited due to ATP binding cassette transporters exporting chemotherapeutic agents
Solution Approach 1:
The patent extracts and targets the specific GPC3 protein expressed on the surface of HCC cells, rather than using general chemotherapy agents that are pumped out by ABC transporters. By isolating and targeting the unique GPC3 antigen, the treatment bypasses the resistance mechanism of ABC transporters that export non-specific chemotherapeutic agents.
Solution Approach 2:
The patent introduces GPC3-specific antibodies or CAR-T cells as intermediary agents that recognize and bind to GPC3 on HCC cells. These intermediaries mediate the immune response or deliver cytotoxic effects specifically to GPC3-positive cells, avoiding the direct chemical interaction that would be blocked by ABC transporters.
2Reliability
If surgery is used to treat HCC, then early-stage cancer can be removed, but it is not effective for late-stage cancer with minimal survival benefit
Solution Approach 1:
The patent develops GPC3-targeted therapies that can be applied across multiple disease stages and patient populations. The same GPC3-specific antibody or CAR-T cell construct can treat both early-stage and late-stage HCC, providing a universal treatment approach that adapts to different disease severities unlike surgery which is stage-limited.
3Measurement precision
If conventional antibodies are used, then GPC3 can be recognized, but they may not specifically distinguish cell surface-bound GPC3 from soluble GPC3
Solution Approach 1:
The patent designs antibody constructs with specific local properties that enable them to bind preferentially to cell surface-bound GPC3. This may involve engineering Fc regions with specific effector functions, optimizing affinity for the conformational epitope presented on the cell surface, or designing bispecific constructs that simultaneously bind GPC3 and immune cells, creating localized high-concentration binding at the cell surface.
Data Source
AI summary
The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.